Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Journal: The Lancet. Haematology
Published: July 27, 2020
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 12, 2019
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
Journal: The Lancet. Haematology
Published: January 04, 2019
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
Journal: Blood
Published: May 10, 2018
A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia.
Journal: The oncologist
Published: April 13, 2017
Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: November 06, 2013
Showing 1-7 of 7
Last Updated: 09/26/2026